Introduction
============

Infections with community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA) have been reported since the late 1990s ([@B1]). Naimi et al. ([@B2]) defined CA-MRSA as follows: 1) an MRSA infection identified within 48 hours of admission to a hospital; 2) without a history of hospitalization, surgery, dialysis, or residence in a long-term care facility within one year of the MRSA culture date; 3) without a permanent indwelling catheter or percutaneous medical device present at the time of culture; and 4) without a known positive culture for MRSA prior to the study period. CA-MRSA most commonly produces skin and soft-tissue infections, and severe and life-threatening infections such as sepsis, meningitis and necrotizing pneumonia are relatively rare ([@B3]). Necrotizing pneumonia is a severe form of lung disease associated with the formation of abscesses and cavitation within the lung parenchyma, and has a high mortality rate. In addition, severe necrotizing pneumonia caused by CA-MRSA, in particular the strain producing Panton-Valentine leukocidin (PVL), is associated with a very high fatality rate ([@B4]).

We describe a case of necrotizing pneumonia caused by CA-MRSA with the PVL gene and the rapidly progressive formation of multiple cavities in the bilateral lung fields. The disease progression was stopped by the immediate administration of vancomycin (VCM).

Case Report
===========

A 66-year-old man noted an influenza-like illness in February 2017. The patient was a farmer and a current heavy smoker (96 pack-years). He had never traveled abroad, had no recent contact with foreigners, and had a history of pneumonia and acute renal failure in his teens and twenties, respectively. He had been healthy and had no medical problems until twelve days before his admission to our hospital, when he noted fever, cough and arthralgia. He had not previously been vaccinated for influenza. He was first diagnosed with type-A influenza and treated with oseltamivir in a nearby clinic. His high fever continued and his dyspnea gradually progressed after several days; thus, he was admitted to a nearby hospital. Computed tomography (CT) scans of the chest showed bilateral multiple granular shadows and patchy opacities. MRSA was detected in a sputum culture obtained on admission. He was treated with antibiotics (sulbactam/ampicillin, SBT/ABPC; and levofloxacin). Although his C-reactive protein (CRP) level was reduced (from 40.0 to 23.0 mg/dL), the bilateral consolidation on chest X-ray films worsened. Thus, he was transferred to our hospital due to progressive and refractory pneumonia.

On admission to our hospital, the patient was conscious and his vital signs were as follows: temperature, 38.2 ºC; blood pressure, 149/79 mmHg; heart rate, 118 beats/minute; respiratory rate, 20 breaths/minute. The oxygen saturation was 98% under 3 L/min of oxygen inhalation. A physical examination revealed no abnormal findings except for faint coarse crackles in the bilateral lungs. No wounds were observed on his body, arms, or legs. A laboratory analysis revealed leukocytosis with predominant neutrophils and hypoalbuminemia, and his CRP level was elevated at 19.14 mg/dL (shown in [Table 1](#t001){ref-type="table"}). His procalcitonin level was 2.43 ng/mL, and his soluble interleukin 2 receptor (sIL-2R) was also elevated (2,475.0 U/mL; normal range, \<500 U/mL). The levels of rheumatoid factor, antinuclear antibodies, and anticytoplasmic antibodies were all within the normal ranges. A chest X-ray film showed bilateral infiltration, which had progressed in comparison to the X-ray films obtained at the previous hospital ([Fig. 1](#g001){ref-type="fig"}). In addition, chest CT showed the rapidly progressive formation of multiple cavities and surrounding ground-grass opacities with bilateral pleural effusion in the bilateral lungs, whereas the CT scans obtained at the former hospital showed only patchy opacity, small nodules, and no cavities ([Fig. 2](#g002){ref-type="fig"}).

###### 

Laboratory Findings on Admission to Our Hospital.

  -------------- -- -------- ----------- ------ ---------- -- ------------ ------- ------ ----------------- -- ------- -------
  Hematology        LDH                  188    U/L           KL-6                 69.0   U/mL                         
  WBC               14,000   /μL                ALP           556          U/L            SP-A                 84.9    ng/mL
  Seg               77.0     \%                 γ-GTP         362          U/L            SP-D                 36.9    ng/mL
  Stab              8.0      \%                 TP            5.3          g/dL           RF                   5       U/mL
  Mon               5.0      \%                 ALB           1.8          g/dL           ANA                  \<x40   
  Lym               10.0     \%                 CRE           0.84         mg/dL          PR3-ANCA             \<0.6   U/mL
  Eos               0.0      \%                 BUN           16           mg/dL          MPO-ANCA             \<1.0   U/mL
  Bas               0.0      \%                 Na            131          mEq/L          Mycoplasma Ab        \<x40   
  RBC               387      ×10^4^/μL          K             3.9          mEq/L          Cryptococcus Ag      (-)     
  Hgb               12.7     g/dL               Cl            97           mEq/L          Aspergillus Ag       \>5.0   
  Hct               34.9     \%                 Serology      Candida Ag           (-)                                 
  PLT               42.0     ×10^4^/μL          CRP           19.14        mg/dL          β-D-glucan           13.4    pg/mL
  ESR               71       mm/h               PCT           2.43         ng/mL          T-SPOT                       
  Biochemistry      BNP                  37.0   pg/mL         ESAT-6               0      spot                         
  T-Bil             1.2      mg/dL              CEA           2.1          ng/mL          CFP-10               0       spot
  AST               36       U/L                CA19-9        2.9          U/mL           Influenza A          (-)     
  ALT               42       U/L                sIL-2R        2,475.0      U/mL           Influenza B          (-)     
  -------------- -- -------- ----------- ------ ---------- -- ------------ ------- ------ ----------------- -- ------- -------

![Chest X-ray films obtained in the former hospital (A) and on admission to our hospital in February 2017 (B). Bilateral infiltrates, mainly in middle field, progressed rapidly within about one week.](1349-7235-58-0685-g001){#g001}

![Chest computed tomography on admission at the previous hospital showed bilateral multiple patchy shadows and ground-grass opacities (A). Rapidly progressive consolidations and the formation of cavities with bilateral pleural effusion were seen on chest CT scans obtained on admission to our hospital after a short period of time (B).](1349-7235-58-0685-g002){#g002}

As the SBT/ABPC regimen used at the former hospital seemed to be somewhat effective, we began treatment with it again. The formation of multiple cavities shown by CT scans suggested different possible diagnoses, including multiple lung abscesses, invasive pulmonary aspergillosis, cryptogenic organizing pneumonia, granulomatosis with polyangiitis, septic embolism, and pulmonary malignancies. The patient\'s blood culture sets were negative. Echocardiography showed no vegetation in the cardiac valves and deep vein thrombosis was not observed on endovascular echography, indicating that septic embolism was unlikely. On day two, we performed bronchoscopy for the suctioning of purulent sputum, biopsy, and brushing cytology. This was performed by endobronchial ultrasonography with a guide-sheath method. A specimen was obtained from the area of consolidation in the left lingular lobe. We detected a large number of grapelike clusters of gram-positive cocci by gram staining, and a cytological examination showed neutrophils with phagocytosis of bacterium. A histopathological examination showed necrosis with inflammatory exudate surrounding the neutrophils, fibrin deposition, and some immature fibrosis, indicating pulmonary abscesses.

On day four, the patient was treated with VCM at a starting dose of 1,000 mg/day, which was subsequently increased to 1,500 mg/day according to its trough value (final concentration, 17.4 μg/mL). MRSA isolated from sputum was sensitive to trimethoprim/sulfamethoxazole, erythromycin (EM), minocycline (MINO), and clindamycin (CLDM), as well as VCM (minimal inhibitory concentration, MIC ≤1 μg/mL). Furthermore, type IV staphylococcus cassette chromosome *mec* (SCC*mec*) and genes encoding Panton-Valentine leucocidin (PVL) were identified by a polymerase chain reaction ([@B5]) of the strain of MRSA isolated from the patient\'s sputum. These molecular characteristics of the strain were compatible with CA-MRSA. Considering the definition established by Naimi et al. ([@B2]), we diagnosed the present case with necrotizing pneumonia due to CA-MRSA.

The administration of VCM reduced the patient\'s temperature, white blood cell count, and serum level of CRP. The patient\'s oxygenation status also resolved, and the pulmonary opacities on the patient\'s chest X-ray film improved ([Fig. 3](#g003){ref-type="fig"}). On the 27th day of admission, we changed VCM to linezolid (MIC 2 μg/mL) due to drug-induced fever. On the 30th and 40th days of admission, we confirmed that the patient\'s sputum was not positive for any strains of bacteria, including MRSA, and the patient discharged from the hospital on the 41st day of admission with the complete improvement of his general condition. Chest CT scans at six months after treatment showed the disappearance of the multiple cavities.

![The clinical course after admission to our hospital. The patient was treated with vancomycin, which was subsequently escalated according to its trough value. Although low-grade fever continued, inflammatory markers, including the leukocyte count and serum level of CRP, gradually improved. On day 27, we changed vancomycin to linezolid because of drug-associated fever. At approximately one month after admission, MRSA was no longer detected in the patient's sputum and the bilateral multiple consolidations and cavities had improved. Anti-MRSA agents were stopped and he was discharged from our hospital.](1349-7235-58-0685-g003){#g003}

Discussion
==========

Community-acquired pneumonia (CAP) is most commonly caused by *Streptococcus pneumoniae*. *Staphylococcus aureus* (SA) pneumonia is the third-most common cause of CAP, reportedly causing 4.2% of all cases of CAP in Japan ([@B6]). Furthermore, CAP caused by MRSA is reported to cause 28.4% of all cases of SA pneumonia. We diagnosed the present case with necrotizing pneumonia caused by CA-MRSA, as the case met all of the criteria for the CA-MRSA definition indicated by Naimi et al. ([@B2]), and the patient had no specific medical history. Skin and soft tissue infections are often caused by CA-MRSA, whereas respiratory or urinary tract infections are less likely to be caused by community-acquired strains ([@B3],[@B7]). In addition, there have been several reports of necrotizing pneumonia induced by CA-MRSA. [Table 2](#t002){ref-type="table"} shows all of the cases of CA-MRSA necrotizing pneumonia reported in Japan. The first report, published in 2008 by Tomita et al., was the first of only eight reported cases ([@B8]). All but one case (Case 7, [Table 2](#t002){ref-type="table"}) showed consolidation, and radiology demonstrated cavity formation in six cases. Two patients died despite the administration of anti-MRSA agents and intensive care. These patients had bilateral lesions, and MRSA was isolated from blood samples, which are suggested to be factors that predict a poor prognosis in patients with CA-MRSA necrotizing pneumonia.

###### 

Case Series of Necrotizing Pneumonia Induced by CA-MRSA Reported from Japan.

  No   Year           Age   Sex   Nationality        Past History                                       Consolidation   Cavity   Pleural Effusion   Bilaterality   Specimen         PVL   Therapy         Outcome   Ref.
  ---- -------------- ----- ----- ------------------ -------------------------------------------------- --------------- -------- ------------------ -------------- ---------------- ----- --------------- --------- --------
  1    2008           89    M     Japanese           Gastric cancer Ileus Pneumonia                     \+              \+       \+                 No             Sputum           \-    TEIC            Dead      \[8\]
  2    2008           15    M     Japanese           Clavicle fracture MSSA infection Piriformis peri   \+              \+       \+                 No             Sputum           \-    TEIC            Alive     \[8\]
  3    2009           1     M     Japanese           None                                               \+              \-       \+                 Yes            Blood Effusion   \+    VCM             Dead      \[20\]
  4    2012           16    F     Vietnamese         None                                               \+              \+       \-                 Yes            Sputum           \+    LZD CLDM        Alive     \[14\]
  5    2013           54    F     Japanese           ITP                                                \+              \+       \-                 Yes            BALF Sputum      \-    TEIC VCM        Alive     \[22\]
  6    2013           31    M     African-American   None                                               \+              \+       \-                 Yes            Sputum Blood     \+    VCM             Alive     \[23\]
  7    2014           45    M     Japanese           Liver cirrhosis                                    \-              \-       \-                 No             Sputum           NA    LZD TEIC        Alive     \[24\]
  8    2017           78    M     Japanese           Hypertension Diabetes                              \+              \+       \-                 Yes            Sputum Blood     \-    LZD TEIC CLDM   Dead      \[25\]
  9    Present Case   66    M     Japanese           Pneumonia Renal Failure                            \+              \+       \+                 Yes            Sputum Tissue    \+    VCM LZD         Alive     

ITP: idiopathic thrombocytopenic purpura, MSSA: methicillin-sensitive *Staphylococcus aureus*, BALF: bronchial alveolar lavage fluid, N/A: not available, TEIC: teicoplanin, VCM: vancomycin, LZD: linezolid, CLDM: clindamycin

It has been shown that methicillin-susceptible *Staphylococcus aureus* strains become MRSA strains through the acquisition of the SCC*mec* element carrying the *mec*A gene, which is responsible for methicillin resistance ([@B9]). It is also reported that, in Japan, healthcare-associated MRSA (HA-MRSA) is likely to have SCC*mec* type II, while CA-MRSA is more likely to have type IV ([@B10]). Similarly, in the United States and Europe, CA-MRSA is likely to have SCC*mec* type IV. SCC*mec* type IV is known to have the PVL gene, which is a toxin that is known to cause white blood cell destruction ([@B11]). As shown in [Table 2](#t002){ref-type="table"}, among the reported cases of necrotizing pneumonia caused by CA-MRSA, only two adult cases and one pediatric case were shown to have the PVL gene. Interestingly, these two adult cases were not Japanese (one was African-American, and the other Vietnamese), whereas the present case was a native-born Japanese individual with no history of any recent contact with foreigners. Considering that only 2.3% of SCC*mec* type IV strains in Japan have PVL ([@B12]), the present case is thought to be quite rare.

Prior respiratory tract infection, especially infection caused by influenza, is likely to precede CA-MRSA necrotizing pneumonia. Cheng et al. reported a fatal adult case of CA-MRSA infection associated with the H1N1 influenza virus ([@B13]). In Japan, a case of toxic shock syndrome associated with the 2009 H1N1 influenza virus pandemic and CA-MRSA infection in a 16-year-old Vietnamese girl was reported by Kashiwada et al. (Case 4, [Table 2](#t002){ref-type="table"}) ([@B14]). Our case also had a history of influenza infection. Viral infections and other types of infection damage epithelial cells in the airway, resulting in the easy engraftment of PVL-positive MRSA to the basement membrane ([@B15]). Subsequently, PVL can cause pulmonary necrosis through tissue destruction with the infiltration of neutrophils and macrophages. CA-MRSA necrotizing pneumonia with the PVL gene is reported to be associated with rapid tissue destruction and cavity formation. As indicated in [Table 2](#t002){ref-type="table"}, two of three PVL-positive CA-MRSA cases showed cavity formation in the bilateral lung fields. The radiological findings in our case were typical of and compatible with PVL-positive MRSA necrotizing pneumonia. The prior influenza infection was considered to be a trigger for the development of necrotizing pneumonia.

As shown in [Table 1](#t001){ref-type="table"}, our patient had an elevated serum *Aspergillus* antigen level. It was therefore important to exclude invasive pulmonary aspergillosis as a potential cause of the aggressive cavity formation in the bilateral lungs. Certain food products and antibiotics have been associated with false-positive reactions in Pastorex *Aspergillus* latex agglutination tests ([@B16]). In particular, a number of false-positives have been reported in patients treated with piperacillin/tazobactam ([@B17]). ABPC, which is obtained from the genus *Penicillium*, which contains galactofuran-bearing molecules in the cell wall could also cause a false-positive reaction in a *Aspergillus* antigen test ([@B18]). Thus, in the present case, we considered the *Aspergillus* antigen positivity of the present case to represent a false-positive result and attributed it to the administration of SBT/ABPC in the previous hospital.

CA-MRSA isolates are generally sensitive to various antibiotics other than β-lactams ([@B19]). In the present case, MRSA isolated from the sputum and bronchial scrapings displayed sensitivity to trimethoprim/sulfamethoxazole, EM, CLDM, and MINO, which are usually resisted by HA-MRSA ([@B19]). These findings suggested the possibility of CA-MRSA infection, and the susceptibility profile in our case was similar to a case of CA-MRSA necrotizing pneumonia with PVL that was reported by Ito et al. ([@B20]). In contrast, six of the eight cases listed in [Table 2](#t002){ref-type="table"} had MRSA isolates that were resistant to EM, whereas all cases, including our own, showed susceptibility to MINO (data not shown). According to a previous report, some cases of CA-MRSA infection showed resistance to macrolide antibiotics ([@B19]). Thus, if antimicrobial susceptibility testing shows a different profile from HA-MRSA, the possibility of CA-MRSA infection should be considered.

In conclusion, CA-MRSA pneumonia, especially with PVL production, should be suspected, even in healthy patients, when they show the rapidly progressive formation of multiple cavities. As CA-MRSA producing PVL has a very high fatality rate ([@B21]), immediate treatment with anti-MRSA agents is critical for halting the progression and preventing a fatal outcome.
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